AstraZeneca Reiterates 80 Billion USD Revenue Target for 2030, Driven by Oncology Drugs Boosting Q2 Growth
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Groonghui, July 27 — AstraZeneca reported Q2 revenue of $15.38 billion, with oncology business revenue increasing by 15% year-on-year, advancing towards its 2030 revenue target of $80 billion. The CEO expressed confidence in the R&D pipeline, stating that with the launch of new drugs such as Baxfendy and Etcamah, over half of the plan to launch 20 new drugs by 2030 has already been completed.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Crypto prices
More
Bitcoin
BTC
$74,193.09
+1.15%
Ethereum
ETH
$2,079.79
+2.40%
Tether USDt
USDT
$0.9989
-0.01%
BNB
BNB
$684.68
+1.12%
USDC
USDC
$0.9998
-0.01%
XRP
XRP
$1.07
+2.40%
Solana
SOL
$84.85
+3.13%
TRON
TRX
$0.3162
-0.86%
Hyperliquid
HYPE
$73.59
+1.91%
Zcash
ZEC
$1,000.76
-8.32%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now